JP2010532381A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010532381A5 JP2010532381A5 JP2010515223A JP2010515223A JP2010532381A5 JP 2010532381 A5 JP2010532381 A5 JP 2010532381A5 JP 2010515223 A JP2010515223 A JP 2010515223A JP 2010515223 A JP2010515223 A JP 2010515223A JP 2010532381 A5 JP2010532381 A5 JP 2010532381A5
- Authority
- JP
- Japan
- Prior art keywords
- nitrogen
- compound
- optionally substituted
- sulfur
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 86
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 67
- 229910052757 nitrogen Inorganic materials 0.000 claims description 50
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 44
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 44
- 229910052760 oxygen Inorganic materials 0.000 claims description 44
- 239000001301 oxygen Chemical group 0.000 claims description 44
- 229910052717 sulfur Chemical group 0.000 claims description 44
- 239000011593 sulfur Chemical group 0.000 claims description 44
- 125000005842 heteroatom Chemical group 0.000 claims description 42
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000004429 atom Chemical group 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 125000002950 monocyclic group Chemical group 0.000 claims description 18
- 125000002619 bicyclic group Chemical group 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 208000020084 Bone disease Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000001931 aliphatic group Chemical group 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 230000001066 destructive effect Effects 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 208000014951 hematologic disease Diseases 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 230000002584 immunomodulator Effects 0.000 claims description 4
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 4
- 230000001861 immunosuppressant effect Effects 0.000 claims description 4
- 239000003018 immunosuppressive agent Substances 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 4
- 239000003900 neurotrophic factor Substances 0.000 claims description 4
- -1 oxadiadiolyl Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000001425 triazolyl group Chemical group 0.000 claims description 4
- 208000019838 Blood disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 150000008624 imidazolidinones Chemical class 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000001926 lymphatic effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 102000009929 raf Kinases Human genes 0.000 claims description 2
- 108010077182 raf Kinases Proteins 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims description 2
- 125000005306 thianaphthenyl group Chemical group 0.000 claims description 2
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000037964 urogenital cancer Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94731907P | 2007-06-29 | 2007-06-29 | |
| PCT/US2008/068789 WO2009006404A2 (en) | 2007-06-29 | 2008-06-30 | Heterocyclic compounds useful as raf kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010532381A JP2010532381A (ja) | 2010-10-07 |
| JP2010532381A5 true JP2010532381A5 (enExample) | 2012-07-26 |
Family
ID=40015666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010515223A Pending JP2010532381A (ja) | 2007-06-29 | 2008-06-30 | Ｒａｆキナーゼ阻害剤として有用な複素環式化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7968536B2 (enExample) |
| EP (1) | EP2167497A2 (enExample) |
| JP (1) | JP2010532381A (enExample) |
| CN (1) | CN101743242A (enExample) |
| AU (1) | AU2008273017C1 (enExample) |
| CA (1) | CA2694284A1 (enExample) |
| NZ (1) | NZ582349A (enExample) |
| WO (1) | WO2009006404A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| AP2739A (en) * | 2008-09-26 | 2013-09-30 | Boehringer Ingelheim Int | Azaindazole compounds as CCRI receptor antagonists |
| CN102361859A (zh) * | 2008-12-30 | 2012-02-22 | 米伦纽姆医药公司 | 用作Raf激酶抑制剂的杂芳基化合物 |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| US9034850B2 (en) | 2009-11-20 | 2015-05-19 | Sk Chemicals Co., Ltd. | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same |
| WO2012142029A2 (en) | 2011-04-10 | 2012-10-18 | Florida A&M University | Serms for the treatment of estrogen receptor-mediated disorders |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| CA2862346A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| EP2825533B1 (en) | 2012-03-13 | 2016-10-19 | Basf Se | Fungicidal pyrimidine compounds |
| CN102936251A (zh) * | 2012-11-05 | 2013-02-20 | 上海毕得医药科技有限公司 | 一种吡咯并[2,3-d]嘧啶衍生物的制备方法 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| US9045477B2 (en) | 2013-03-15 | 2015-06-02 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| US9776996B2 (en) | 2013-03-15 | 2017-10-03 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015036059A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
| CA2923101A1 (en) | 2013-09-16 | 2015-03-19 | Basf Se | Fungicidal pyrimidine compounds |
| CN104761502A (zh) * | 2014-01-03 | 2015-07-08 | 中国药科大学 | 苯并咪唑衍生物、其制法及医药用途 |
| US9914698B2 (en) | 2014-01-08 | 2018-03-13 | Shanghai Jiaotong University School Of Medicine | Stearoyl amino acid salt and preparation method and application thereof |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| JP6246901B2 (ja) * | 2015-01-14 | 2017-12-13 | 株式会社東芝 | 非水電解質電池及び電池パック |
| EP3185341B1 (fr) * | 2015-12-21 | 2019-09-11 | The Swatch Group Research and Development Ltd | Cathode de pile métal/air et procédés de fabrication d'une telle cathode |
| JP2019196307A (ja) | 2016-09-15 | 2019-11-14 | 武田薬品工業株式会社 | 複素環アミド化合物 |
| CA3037456A1 (en) | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| US11471538B2 (en) | 2017-02-10 | 2022-10-18 | INSERM (Institut National de la Santéet de la Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway |
| CN106928152A (zh) * | 2017-03-03 | 2017-07-07 | 符爱清 | 一种尿嘧啶的制备方法 |
| IL270224B1 (en) | 2017-05-02 | 2024-04-01 | Novartis Ag | Combination therapy employing trametinib and a defined raf inhibitor |
| MX391164B (es) | 2017-05-30 | 2025-03-21 | Dot Therapeutics 1 Inc | Metodo para producir compuesto opticamente activo |
| WO2019067623A1 (en) * | 2017-09-27 | 2019-04-04 | The Regents Of The University Of California | POWERFUL ANTIVIRAL COMPOUNDS CONTAINING PYRIDINE |
| EP3732285A1 (en) | 2017-12-28 | 2020-11-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| WO2019148244A1 (en) * | 2018-02-01 | 2019-08-08 | The University Of Sydney | Anti-cancer compounds |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| EP4074700A4 (en) | 2019-12-10 | 2024-02-07 | Shionogi & Co., Ltd | HISTONE DEACETYLASE INHIBITOR COMPRISING AROMATIC HETEROCYCLIC GROUP CONTAINING NITROGEN |
| US20230159492A1 (en) * | 2020-03-02 | 2023-05-25 | Sironax Ltd. | Ferroptosis inhibitors - diarylamine para-acetamides |
| IL300113A (en) * | 2020-07-28 | 2023-03-01 | Jazz Pharmaceuticals Ireland Ltd | Compressed cyclic RAF inhibitors and methods of using them |
| EP4448492A1 (en) | 2021-12-17 | 2024-10-23 | Reglagene, Inc. | Compositions and methods of making and using small molecules in the treatment of cancer |
| WO2024182556A1 (en) | 2023-02-28 | 2024-09-06 | Reglagene, Inc. | Compositions and methods for making and using small molecules for the treatment of health conditions |
| CN117567388B (zh) * | 2023-11-14 | 2024-04-16 | 济南悟通生物科技有限公司 | 一种2-乙酰基-5-噻唑甲酸的合成方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US5563158A (en) | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| CA2228953A1 (en) | 1995-09-26 | 1997-04-03 | Takeda Chemical Industries, Ltd. | Phosphorylamides, their preparation and use |
| CA2240439A1 (en) | 1995-12-22 | 1997-07-03 | The Dupont Merck Pharmaceutical Company | Novel integrin receptor antagonists |
| US5760028A (en) | 1995-12-22 | 1998-06-02 | The Dupont Merck Pharmaceutical Company | Integrin receptor antagonists |
| US5872136A (en) | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| WO1997036901A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| US6017925A (en) | 1997-01-17 | 2000-01-25 | Merck & Co., Inc. | Integrin antagonists |
| AU6422798A (en) | 1997-03-25 | 1998-10-20 | Takeda Chemical Industries Ltd. | Stabilized urease inhibitor |
| AU6780398A (en) | 1997-03-28 | 1998-10-22 | Du Pont Merck Pharmaceutical Company, The | Heterocyclic integrin inhibitor prodrugs |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
| JPH11209366A (ja) | 1998-01-23 | 1999-08-03 | Nissan Chem Ind Ltd | クロマン誘導体及び心不全治療薬 |
| EP0982030A3 (en) | 1998-08-17 | 2000-05-10 | Pfizer Products Inc. | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands |
| EP1058549A4 (en) | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
| AU3514200A (en) | 1999-03-10 | 2000-09-28 | Merck & Co., Inc. | 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| EP1161431A4 (en) | 1999-03-10 | 2002-04-24 | Merck & Co Inc | 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASE HORMONES |
| AU2830800A (en) | 1999-03-25 | 2000-10-16 | Nissan Chemical Industries Ltd. | Chroman derivatives |
| US6127382A (en) | 1999-08-16 | 2000-10-03 | Allergan Sales, Inc. | Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| EP1235807A1 (en) | 1999-11-24 | 2002-09-04 | Millennium Pharmaceuticals, Inc. | B-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa |
| GB0007245D0 (en) | 2000-03-24 | 2000-05-17 | Zeneca Ltd | Chemical compounds |
| US6414013B1 (en) * | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| CA2413957A1 (en) | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| AU2002338334B8 (en) | 2001-04-03 | 2008-09-18 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists |
| NZ533440A (en) * | 2001-12-24 | 2006-08-31 | Astrazeneca Ab | Substituted quinazoline derivatives as inhibitors of aurora kinases |
| TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US20040048866A1 (en) | 2002-03-08 | 2004-03-11 | Teodozyj Kolasa | Indazole derivatives that are activators of soluble guanylate cyclase |
| US7202244B2 (en) | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
| US20040082627A1 (en) | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
| CA2491895C (en) | 2002-07-09 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| EP1400244A1 (en) | 2002-09-17 | 2004-03-24 | Warner-Lambert Company LLC | New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors |
| WO2004028526A1 (ja) | 2002-09-25 | 2004-04-08 | Santen Pharmaceutical Co., Ltd. | ベンズアミド誘導体を有効成分とするリウマチ治療剤 |
| JP2004161716A (ja) | 2002-11-15 | 2004-06-10 | Takeda Chem Ind Ltd | Ｊｎｋ阻害剤 |
| WO2004110350A2 (en) | 2003-05-14 | 2004-12-23 | Torreypines Therapeutics, Inc. | Compouds and uses thereof in modulating amyloid beta |
| JP2004339159A (ja) | 2003-05-16 | 2004-12-02 | Sankyo Co Ltd | ４−オキソキノリン誘導体を含有する医薬組成物 |
| DE10328999B4 (de) | 2003-06-27 | 2006-08-31 | Lanxess Deutschland Gmbh | Verfahren zur Herstellung von Metallkomplexpigmenten mit niedriger Dispergierhärte |
| CA2531333A1 (en) | 2003-07-16 | 2005-02-10 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| CN100549014C (zh) | 2003-07-16 | 2009-10-14 | 詹森药业有限公司 | 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物 |
| JP2007507531A (ja) | 2003-09-30 | 2007-03-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| GB2432834A (en) | 2004-01-12 | 2007-06-06 | Cytopia Res Pty Ltd | Selective Kinase Inhibitors |
| WO2005072733A1 (en) | 2004-01-20 | 2005-08-11 | Millennium Pharmaceuticals, Inc. | Dyarylurea compounds as chk-1 inhibitors |
| TW200616974A (en) * | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
| ATE485300T1 (de) * | 2004-07-16 | 2010-11-15 | Sunesis Pharmaceuticals Inc | Als aurora-kinase-inhibitoren nutzbare thienopyrimidine |
| CA2584485C (en) | 2004-10-20 | 2013-12-31 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| EP1828186A1 (en) * | 2004-12-13 | 2007-09-05 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| US8211929B2 (en) | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| WO2006076442A2 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| CN102361859A (zh) | 2008-12-30 | 2012-02-22 | 米伦纽姆医药公司 | 用作Raf激酶抑制剂的杂芳基化合物 |
-
2008
- 2008-06-30 CN CN200880022610A patent/CN101743242A/zh active Pending
- 2008-06-30 NZ NZ582349A patent/NZ582349A/en not_active IP Right Cessation
- 2008-06-30 CA CA2694284A patent/CA2694284A1/en not_active Abandoned
- 2008-06-30 US US12/164,905 patent/US7968536B2/en not_active Expired - Fee Related
- 2008-06-30 WO PCT/US2008/068789 patent/WO2009006404A2/en not_active Ceased
- 2008-06-30 EP EP08781174A patent/EP2167497A2/en not_active Withdrawn
- 2008-06-30 JP JP2010515223A patent/JP2010532381A/ja active Pending
- 2008-06-30 AU AU2008273017A patent/AU2008273017C1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010532381A5 (enExample) | ||
| CN114751903B (zh) | 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途 | |
| JP7720840B2 (ja) | Ｆｇｆｒ阻害剤としての三環式複素環 | |
| CN103384670B (zh) | 取代的咪唑并[1,2-b]哒嗪 | |
| KR101829940B1 (ko) | 프탈라지논 케톤 유도체, 이의 제조방법, 및 이의 약학적 용도 | |
| RU2589696C2 (ru) | КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 4 ИЛИ ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 6 (CDK4/6) И ИНГИБИТОР mTOR, ДЛЯ ЛЕЧЕНИЯ РАКА | |
| ES2968252T3 (es) | Compuesto 8,9-dihidroimidazol[1,2-a]pirimido[5,4-e]pirimidin-5(6H)-cetona | |
| ES2396177T3 (es) | Pirimidinas bicíclicas fusionadas | |
| CN113454080A (zh) | 化合物、药物组合物和制备化合物的方法以及其使用方法 | |
| EP3889152A1 (en) | Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof | |
| JP2010532380A5 (enExample) | ||
| WO2023066350A1 (zh) | Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 | |
| EP3006445B1 (en) | Bisulfate of janus kinase (jak) inhibitor and preparation method therefor | |
| CN114174292A (zh) | 作为atr激酶抑制剂的取代的2-吗啉代吡啶衍生物 | |
| ES2558780T3 (es) | Imidazopiridazinas como inhibidores de la cinasa Akt | |
| EP3660018A1 (en) | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine | |
| CN110167941B (zh) | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 | |
| RS52313B (sr) | Jedinjenja za inhibiciju napredovanja mitoze | |
| CN111320624B (zh) | 三唑并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途 | |
| WO2023072297A1 (zh) | 含氮的四环化合物、其制备方法及其在医药上的应用 | |
| CN115385937A (zh) | 嘧啶并环烷基类化合物、其制备方法及其在医药上的应用 | |
| JP2025525478A (ja) | Ｐｒｍｔ５・ｍｔａを阻害できる複素環化合物及びその用途 | |
| JP6736545B2 (ja) | 大環状ｒｉｐ２キナーゼ阻害剤 | |
| ES2589955T3 (es) | Pirazolopirimidinas sustituidas como inhibidores de la quinasa Akt | |
| EP2651949B1 (en) | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway |